C3orf30 Inhibitors
C3orf30 inhibitors encompass a range of chemical compounds that interact with distinct cellular processes to suppress the functional activity of C3orf30. Staurosporine, for instance, by inhibiting a broad spectrum of protein kinases, could prevent the phosphorylation and subsequent activation of C3orf30 if it is regulated by specific kinases. Similarly, Rapamycin and LY 294002 would act upstream to diminish C3orf30 activity by inhibiting mTOR and PI3K, respectively, pathways that, if connected to C3orf30, would lead to its reduced activity through a decrease in anabolic process signaling or protein phosphorylation. PD 98059 and U0126, as inhibitors of the MEK enzyme, would attenuate the MAPK/ERK pathway, resulting in a potential decrease in C3orf30 activity if it were a downstream effector. Furthermore, the p38 MAP kinase inhibitor SB 203580 could indirectly lead to the inhibition of C3orf30 by reducing the regulatory influence of the p38 MAPK pathway on this protein.
The action of several other inhibitors further elucidates the potential regulatory mechanisms on C3orf30. Cyclosporin A, by inhibiting calcineurin, could prevent the dephosphorylation and activation of C3orf30, assuming it undergoes regulation by this phosphatase. Chelerythrine and W-7, by inhibiting PKC and antagonizing calmodulin, respectively, could impede C3orf30 activation if it is dependent on either of these calcium-related signaling molecules. Triciribine, targeting Akt, and BAPTA/AM, chelating intracellular calcium, would similarly suppress C3orf30 activity by interfering with downstream signaling cascades reliant on these molecules. Lastly, 1NM-PP1's selective inhibition of the Gsα subunit suggests a decrease in C3orf30 activity if it is modulated by G-protein-coupled receptor pathways. Collectively, these compounds illustrate a spectrum of biochemical interventions that, while converging on the inhibition of C3orf30, highlight the multifaceted nature of cellular regulation and the complexity of targeting a single protein through diverse signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can indirectly inhibit C3orf30 if the protein's function is regulated by phosphorylation. By blocking the kinase that phosphorylates C3orf30, Staurosporine would lead to a decrease in C3orf30 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can indirectly diminish C3orf30 activity if C3orf30 is a downstream effector of the mTOR signaling pathway. Inhibition of mTOR can lead to a general downregulation of anabolic processes including those in which C3orf30 might be involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that would lead to a functional inhibition of C3orf30 by decreasing PI3K/Akt signaling, assuming C3orf30 activity is linked to this pathway. Reduced PI3K activity could lead to decreased phosphorylation and activation of proteins that are upstream or parallel to C3orf30. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that could indirectly diminish C3orf30 activity if MEK is upstream of C3orf30. By inhibiting MEK, the MAPK/ERK signaling pathway is downregulated, which could lead to a decrease in C3orf30 activity if it is a part of this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAP kinase inhibitor which might indirectly lead to the inhibition of C3orf30 if p38 MAPK signaling regulates C3orf30 activity. Inhibition of p38 MAPK by SB 203580 would then result in decreased C3orf30 function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A inhibits calcineurin. If C3orf30 is regulated by calcineurin through dephosphorylation, its activity could be diminished by Cyclosporin A through the inhibition of calcineurin, preventing the activation of C3orf30. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is a PKC inhibitor that could lead to the inhibition of C3orf30 if PKC signaling is involved in C3orf30 activation. By inhibiting PKC, Chelerythrine could reduce the phosphorylation and subsequent activity of C3orf30 if it is regulated by PKC. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and could indirectly inhibit C3orf30 by blocking the MAPK/ERK pathway. If C3orf30 is functionally dependent on this pathway, U0126 would lead to its inhibition. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist that could indirectly inhibit C3orf30 if the protein is regulated by calmodulin-mediated processes. By antagonizing calmodulin, W7 could prevent the calcium-dependent activation of C3orf30. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an Akt inhibitor that could lead to the inhibition of C3orf30 if C3orf30 activity is facilitated by Akt signaling. Inhibiting Akt would reduce the phosphorylation and activation of downstream targets, potentially including C3orf30. | ||||||